Method for decreasing inflammation and stress in a mammal

US9415083B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9415083-B2
Application numberUS-1231708-A
CountryUS
Kind codeB2
Filing dateFeb 1, 2008
Priority dateMay 10, 2004
Publication dateAug 16, 2016
Grant dateAug 16, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.

First claim

Opening claim text (preview).

What is claimed: 1. A method for decreasing inflammation and stress in a mammal comprising: administration to a mammal a composition comprising avocado fruit; and wherein said composition comprises amounts of the avocado fruit sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado; wherein administration is daily and the dose of avocado fruit is about 100 mg/kg to about 200 g/kg; and wherein the composition comprises less than 5% of said avocado fruit, by weight of the composition. 2. The method of claim 1 , wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado is from about 0 mg/L to about 100 mg/L. 3. The method of claim 1 , wherein the administration is oral. 4. The method of claim 1 , wherein said composition is selected from the group consisting of pet food, dog food, cat food, treats, chew, biscuits, gravy, sauce, beverage, supplemental water, and combinations thereof. 5. The method of claim 4 , wherein the composition is a nutritionally balanced pet food composition. 6. The method of claim 1 , further comprising animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, lipids, and combinations thereof. 7. The method of claim 1 , wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado is from about 0 mg/L to about 100 mg/L. 8. A method for decreasing inflammation and stress in a mammal comprising: administration to a mammal a composition comprising mannoheptulose; and wherein said composition comprises amounts of the mannoheptulose sufficient to lower the level of a C-reactive protein in the blood of the mammal subsequent to administration of the mannoheptulose; wherein administration is daily and the dose of mannoheptulose is about 2 mg/kg to about 5 mg/kg; and wherein the composition comprises less than 5% of said mannoheptulose, by weight of the composition. 9. The method of claim 8 , wherein the level of said C-reactive protein in the blood subsequent to administration of the mannoheptulose is from about 0 mg/L to about 100 mg/L. 10. The method of claim 8 , wherein the level of said C-reactive protein in the blood subsequent to administration of the mannoheptulose is from about 0.1 mg/L to about 60 mg/L. 11. The method of claim 8 , wherein the level of said C-reactive protein in the blood subsequent to administration of the mannoheptulose is from about 0.2 mg/L to about 40 mg/L. 12. The method of claim 8 , wherein said mannoheptulose is selected from the group consisting of avocado extract, avocado, and combinations thereof. 13. The method of claim 8 , wherein the administration is oral. 14. The method of claim 8 , wherein said composition is selected from the group consisting of pet food, dog food, cat food, treats, chew, biscuits, gravy, sauce, beverage, supplemental water, and combinations thereof. 15. The method of claim 8 , wherein the composition is a nutritionally balanced pet food composition. 16. The method of claim 8 , further comprising animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, lipids, and combinations thereof. 17. A method for decreasing inflammation and stress in a mammal comprising: administration to a mammal a composition comprising avocado extract; and wherein said composition comprises amounts of the avocado extract sufficient to lower the level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado extract; wherein administration is daily and the avocado extract comprises a dose of glucose anti-metabolite at about 2 mg/kg to about 5 mg/kg; and wherein the composition comprises less than 5% of said avocado extract, by weight of the composition. 18. The method of claim 17 , wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado extract is from about 0 mg/L to about 100 mg/L. 19. The method of claim 17 , wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado extract is from about 0.1 mg/L to about 60 mg/L. 20. The method of claim 17 , wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado extract is from about 0.2 mg/L to about 40 mg/L. 21. The method of claim 17 , wherein the administration is oral. 22. The method of claim 17 , wherein said composition is selected from the group consisting of pet food, dog food, cat food, treats, chew, biscuits, gravy, sauce, beverage, supplemental water, and combinations thereof. 23. The method of claim 17 , wherein the composition is a nutritionally balanced pet food composition. 24. The method of claim 17 further comprising animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, lipids, and combinations thereof.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Hypnotics; Sedatives · CPC title

  • Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

  • Drugs for disorders of the nervous system · CPC title

  • Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9415083B2 cover?
A method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
Who is the assignee on this patent?
Massimino Stefan Patrick, Davenport Gary Mitchell, Hayek Michael Griffin, and 3 more
What technology area does this patent fall under?
Primary CPC classification A61K36/54. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).